Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of decitabine development

8 Apr 2008

Abstract excerpt

Decitabine (5-aza-2'-deoxycytidine) is a hypomethylating agent with a dual mechanism of action: reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses. The original studies in the 1980s used decitabine as a classical anticancer drug, at its maximum clinically tolerated dose, 1500 to 2500 mg/m(2) per course. At these doses, decitabine was found to be active in leukemia, but...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18398832
DOI: 10.1002/cncr.23463

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of decitabine developmentPMID 18398832Read ↗

DecitabineSemantic proximity Read ↗

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read ↗

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemiaSemantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Clinical development of demethylating agents in hematologySemantic proximity Read ↗

Recurrent transcriptional responses in AML and MDS patients treated with decitabineSemantic proximity Read ↗

Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumorsSemantic proximity Read ↗

Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemiaSemantic proximity Read ↗

Decitabine: a historical review of the development of an epigenetic drugSemantic proximity Read ↗

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.